AGenda

Welcome Day

Thursday, August 1, 2024

New-York Historical Society, Lobby

6:00 PM - 9:00 PM

World GU Poster Presentation & Welcome Reception

Day One

Friday, August 2, 2024

Breakfast Symposium (Non-CE)

New-York Historical Society

7:30 AM - 8:20 AM

Prostate Cancer: Applying the Goldilocks Principle in Advanced Prostate Cancer: Matching Disease Aggressiveness and Treatment Intensity to Optimize Outcomes

Chair: Alicia Morgans, MD, MPH

New-York Historical Society, General Session

8:40 AM - 10:00 AM

Oligometastatic Prostate Cancer: MDT approach - Surgeons Perspective

Oligometastatic and Oligoprogressive Disease - Radiation Oncology Perspective

Debate: Doublet vs Triplet Therapy in mHSPC

Updates in High-Risk Hormone Sensitive Biochemical Recurrence

Racial Disparities in Prostate Cancer Care

Community Case

Q&A

Networking Break

New-York Historical Society, Lobby

10:10 AM - 10:40 AM

Prostate Cancer: Hot off the FDA presses: Thinking through therapeutic advances and recent approvals in mCRPC

Chair: Alicia Morgans, MD, MPH

New-York Historical Society, General Session

10:40 AM - 12:00 PM

Targeting the Immune Response

Next Generation Radioligand Therapies

Novel Approaches To Treatment Of mCRPC

Updates In Current Approaches To Radioligand Therapy

Debate: PARPinhibitor Combinations - Pro vs Con

Q&A

Lunch Symposium (Non-CE)

New-York Historical Society

12:10 PM - 1:10 PM

Special Session

New-York Historical Society

1:30 PM - 1:50 PM

Leading the Way in Community oncology: an Interview with Dr. Jeff Vacirca

Renal Cell Carcinoma: In the Right Space at the Right Time: Idealized Management of Kidney Cancer

Chair: Dan George, MD

New-York Historical Society, General Session

1:50 PM - 3:00 PM

Community Case

Patient Selection for Adjuvant Treatment and Trials

Molecular Markers of Microscopic Disease

Debate: Upfront vs Delayed Nephrectomy For Low Volume Metastatic RCC

Consolidative Focal Therapy

Q&A

Networking Break

New-York Historical Society, Lobby

3:10 PM - 3:40 PM

Renal Cell Carcinoma: Remixing the Management of Metastatic Renal Cell Carcinoma

Chair: Dan George, MD

New-York Historical Society, General Session

3:40 PM - 5:00 PM

How do we Risk Stratify Beyond IMDC?

Management of Favorable Risk RCC: Goals and Tx Endpoints

Debate: IO/IO vs IO/TKI in the Treatment of Intermediate Risk RCC

Sequential vs Concomitant Therapies

Novel Agents - Where Do We Introduce?

Q&A

Keynote Presentation

New-York Historical Society

5:00 PM - 5:45 PM

Day Two

Saturday, August 3, 2024

Breakfast Symposium (Non-CE)

New-York Historical Society

7:30 AM - 8:20 AM

Featured Session: THE UROMIGOS - The Intersection of Clinical Trials & Community Practice

New-York Historical Society, General Session

8:30 AM - 10:30 AM

Networking Break

New-York Historical Society, Lobby

10:30 AM - 11:00 AM

Tools For Today's Oncologist

Chairs: Jahan Aghalar, MD & Talha Shaikh, MD, MBA

New-York Historical Society, General Session

11:00 AM - 12:00 PM

NGS, Testing & Biomarkers in Genitourinary Cancers

Social Media for the Oncologist

HealthCare Policy

New York Cancer & Blood Specialists/Memorial Sloan Kettering Cancer Center Collaboration Highlights & Best Practices

Q&A

Lunch Symposium (Non-CE)

New-York Historical Society

12:10 PM - 1:10 PM

Bladder Cancer: Multidisciplinary Management of Localized Bladder Cancer

Chair: Shilpa Gupta, MD

New-York Historical Society, General Session

1:30 PM - 2:50 PM

Debate: Chemo-RT vs Radical Cystectomy in the Treatment of MIBC

IBCG Consensus Update on Bladder Preservation in MIBC

Bladder Preservation After Neoadjuvant Treatment in MIBC

Future of Perioperative Therapy in Bladder Cancer

NMIBC - Defining Trial Endpoints

NMIBC- Novel Bladder Sparing Treatments

Community Case

Q&A

Networking Break

New-York Historical Society, Lobby

3:00 PM - 3:30 PM

Bladder Cancer - Personalized Medicine and Novel Agents in Bladder Cancer

Chair: Shilpa Gupta, MD

New-York Historical Society, General Session

3:30 PM - 4:50 PM

Community Case

Choosing First-Line Systemic Treatment in Bladder Cancer

Sequencing of Therapies in the Evolving Paradigm

Role of Biomarkers in Bladder Cancer

Optimizing Dosing of ADCs and Management of Adverse Events

Trial Development in Rare Variant Histologies

Future Of ADCs And Targeted Therapies in mUC

Q&A

Close

Farewell Reception

New-York Historical Society, Lobby

5:00 PM - 7:00 PM

*Agenda is subject to change.

Experience New York

Come for the education.

Stay for the fun.